Bioreactor Market : Worldwide Study on Top Players | Thermo Fisher Scientific, PBS Biotech, GE Healthcare, Merck Group, Cellexus Ltd, Pall Corporation, Sartorius Stedium Biotech Group, Applikon Biotechnology, Inc., GEA Group Aktiengesellschaft, BioTron In

Bioreactor Market size was valued at over USD 500 million in 2016 and expects gains at over 18% by 2024.Rising chronic diseases prevalence, and soaring biopharmaceutical investments will drive the global bioreactor market size. Growing demand for therapeutically effective vaccines, product innovation, and favorable government initiatives to improve healthcare infrastructure will further stimulate business growth.

Development of orphan drugs and personalized medicine should provide effective healthcare by improvements in diagnosis, treatment, and monitoring of chronic diseases. Increasing number of personalized medicines targeting a specific population coupled with rising number of FDA approved orphan drugs has increased bioproduction, accelerating the bioreactors demand over the forecast years.

Request sample copy of this report @ https://www.gminsights.com/request-sample/detail/141

Contract manufacturing organizations (CMOs) are expanding in terms of capabilities and capacities to meet the growing demand of the biopharmaceutical and bioprocessing industry. Increasing number of novel compounds entering the clinical trials coupled with analytical, formulation and cell line development services should keep up the industry trend. Regulatory concerns regarding single use bioreactor, limited storage capacity and vulnerability to leaching may hinder bioreactor market growth. Furthermore, large-scale disposal of plastic derivatives is a growing environmental concern restraining the business growth.

Mammalian cells accounted for over 75% of the bioreactor market share owing to its wide application in production of therapeutic proteins and viral vaccines. Emergence of gene therapy and tissue engineering should boost the industry growth over forecast years.

Yeast cells demand is forecast to witness over 15% CAGR over the forecast years. It manifests probiotic activity when used as single culture or combined with other probiotic strains. Increasing research for industrial scale production of probiotic yeasts will drive the industry expansion over the coming years. The associated benefits of insect cells such as ease of culture, by-product concentration, high tolerance to osmolality, and higher expression levels will prove favorable to global business growth. These factors will increase their use and revenue share in the coming years.

Make Inquiry about this report @ https://www.gminsights.com/inquiry-before-buying/141

Biopharmaceutical manufacturers held more than 30% of industry share in 2016. Increase in number of biopharmaceutical products in pipeline including antibodies and antibody drug conjugates (ADC) coupled with rising number of new facilities to meet the production needs should fuel business growth.

R&D organizations contributed over USD 250 million to the global industry revenue in 2016 and are projected to witness strong growth over the forecast years. Innovators and manufacturers of biopharmaceuticals and biosimilars continue to discover novel products and build pipelines involving biopharmaceuticals. Furthermore, large biopharmaceutical companies and biosimilar producers are entering strategic collaborations with new entrants to facilitate business expansion.

U.S. bioreactor market will exceed USD 600 million estimation by 2024. Increasing number of biopharmaceutical companies responsible for bringing new medicines to patients and their collaborations with venture capital firms, academic institutions, and patients will drive the regional industry share.

Germany market contributed to over 25% of regional revenue share owing to the presence of leading industry players and increasing healthcare expenditure in this region. Favorable regulatory policies for biopharmaceutical approval and technological innovation in bioprocess equipment will propel business growth.

China bioreactor market should witness more than 19% CAGR. Growing population, increasing chronic disease prevalence, rising R&D investment, and unmet healthcare needs will stimulate industry growth. Favorable government policies to encourage biotechnological research and spurring outsourcing trend are forecast to further accelerate the industry expansion.

Some of the major players in the bioreactor market include Sartorius, GE Healthcare, Thermo Fisher Scientific, Eppendorf, and Merck Millipore.

Key strategies adopted by the industry participants include new product launch, mergers and acquisitions, geographical expansion, strategic agreements, and collaborations. For instance, in July 2016, Sartorius acquired U.S based kSep systems, a firm engaged in the development of automated centrifugation systems used in manufacturing cell-based therapeutics, vaccines, and monoclonal antibodies. This acquisition expanded Sartorius’ bioprocessing solutions portfolio.

Global Market Insights, Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider; offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy and biotechnology.

Arun Hegde
Corporate Sales, USA
Global Market Insights, Inc.
Phone: 1-302-846-7766
Toll Free: 1-888-689-0688
Email: sales@gminsights.com
Blog : http://news-researchers.com/

This release was published on openPR.